论文部分内容阅读
目的:探讨食管鳞癌(esophageal squamous cell carcinoma,ESCC)患者肿瘤组织和引流淋巴结(tumor draining lymph node,TDLN)组织吲哚胺2,3-双加氧酶(indoleamine 2,3-dioxygenase,IDO)和桥接整合因子1(bridging integrator 1,BIN1)的表达及其在ESCC进展中的意义。方法:收集2013年4月至2014年7月在河北医科大学第四医院胸外科行肿瘤切除并经病理证实的71例ESCC患者的肿瘤组织、癌旁组织和TDLN标本,其中肿瘤组织以癌旁组织作为对照组,转移淋巴结以未转移淋巴结作为对照组,均采用Real-time PCR法和免疫组化法检测IDO和BIN1表达情况,分析两者表达的相关性及其与患者临床特征的关系。结果:与未转移淋巴结相比,转移淋巴结中IDO mRNA表达水平和蛋白阳性表达率均显著增高(0.47±0.14 vs 0.22±0.09,P<0.01;90.91%vs 67.35%,P=0.042),而BIN1 mRNA表达水平和蛋白阳性表达率均显著降低(0.15±0.11 vs 0.35±0.15,P<0.01;50.00%vs 77.55%,P=0.028)。与癌旁组织相比,肿瘤组织中IDO mRNA表达水平和蛋白阳性表达率均显著增高(0.51±0.12 vs 0.24±0.11,P<0.01;81.69%vs 22.54%,P<0.01),而BIN1 mRNA表达水平和蛋白阳性表达率均显著降低(0.17±0.10 vs 0.41±0.14,P<0.01;19.72%vs 80.28%,P=0.006)。肿瘤组织和TDLN中,IDO蛋白表达与肿瘤侵犯范围、淋巴结转移、临床分期相关,而BIN1蛋白表达与肿瘤分化程度、侵犯范围、淋巴结转移、临床分期相关。结论:ESCC患者肿瘤组织和转移TDLN中IDO表达水平显著提高、BIN1表达水平显著降低与患者临床特征密切相关,可能是影响ESCC进展的重要因素。
Objective: To investigate the expression of indoleamine 2,3-dioxygenase (IDO) in tumor tissues and tumor draining lymph node (TDLN) tissues of patients with esophageal squamous cell carcinoma (ESCC) And bridging integrator 1 (BIN1) expression in ESCC and its significance. Methods: Tumor tissues, paracancerous tissues and TDLN specimens from 71 patients with ESCC confirmed by pathology in the Department of Thoracic Surgery, the Fourth Hospital of Hebei Medical University from April 2013 to July 2014 were collected. Tumor tissues Tissue as control group and non-metastatic lymph node metastasis as control group. Real-time PCR and immunohistochemistry were used to detect the expression of IDO and BIN1, and the correlation between the expression of IDO and BIN1 was analyzed. Results: Compared with non-metastatic lymph nodes, the expression of IDO mRNA and protein in metastatic lymph nodes were significantly increased (0.47 ± 0.14 vs 0.22 ± 0.09, P <0.01; 90.91% vs 67.35%, P = 0.042) mRNA expression and protein positive rate were significantly decreased (0.15 ± 0.11 vs 0.35 ± 0.15, P <0.01; 50.00% vs 77.55%, P = 0.028). The expression of IDO mRNA and protein in tumor tissues were significantly higher than that in adjacent non-cancerous tissues (0.51 ± 0.12 vs 0.24 ± 0.11, P <0.01; 81.69% vs 22.54%, P <0.01) (P <0.01; 19.72% vs 80.28%, P = 0.006, respectively). The expression of IDO protein was correlated with the extent of tumor invasion, lymph node metastasis and clinical stage in tumor tissue and TDLN. The expression of BIN1 protein was correlated with the degree of tumor differentiation, extent of invasion, lymph node metastasis and clinical stage. CONCLUSIONS: The expression of IDO in tumor tissues and metastatic TDLN is significantly increased in ESCC patients. The significant decrease of BIN1 expression is closely related to the clinical features of ESCC patients, which may be an important factor affecting the progression of ESCC.